SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 6,080,000 shares, a decrease of 25.7% from the September 30th total of 8,180,000 shares. Based on an average daily volume of 593,700 shares, the short-interest ratio is presently 10.2 days.
Hedge Funds Weigh In On SELLAS Life Sciences Group
A hedge fund recently bought a new stake in SELLAS Life Sciences Group stock. Renaissance Technologies LLC purchased a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,446 shares of the company's stock, valued at approximately $39,000. Renaissance Technologies LLC owned approximately 0.06% of SELLAS Life Sciences Group at the end of the most recent quarter. 17.38% of the stock is owned by institutional investors.
SELLAS Life Sciences Group Price Performance
Shares of SLS traded up $0.13 during mid-day trading on Friday, reaching $1.23. 1,015,327 shares of the company's stock traded hands, compared to its average volume of 1,096,079. The stock's 50-day moving average is $1.25 and its two-hundred day moving average is $1.28. SELLAS Life Sciences Group has a 12 month low of $0.50 and a 12 month high of $1.72. The stock has a market cap of $71.04 million, a P/E ratio of -1.12 and a beta of 2.39.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Research analysts predict that SELLAS Life Sciences Group will post -0.55 earnings per share for the current year.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
